Clinical Isolates of Mycobacterium tuberculosis in Four European Hospitals Are Uniformly Susceptible to Benzothiazinones
- 1 April 2010
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 54 (4) , 1616-1618
Abstract
The new antitubercular drug candidate 2-[2- S -methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]-8-nitro-6-(trifluoromethyl)-4H-1,3-benzothiazin-4-one (BTZ043) targets the DprE1 (Rv3790) subunit of the enzyme decaprenylphosphoryl-β- d -ribose 2′-epimerase. To monitor the potential development of benzothiazinone (BTZ) resistance, a total of 240 sensitive and multidrug-resistant Mycobacterium tuberculosis clinical isolates from four European hospitals were surveyed for the presence of mutations in the dprE1 gene and for BTZ susceptibility. All 240 strains were susceptible, thus establishing the baseline prior to the introduction of BTZ043 in clinical trials.Keywords
This publication has 7 references indexed in Scilit:
- High Content Screening Identifies Decaprenyl-Phosphoribose 2′ Epimerase as a Target for Intracellular Antimycobacterial InhibitorsPLOS Pathogens, 2009
- Mycobacterium Tuberculosis: Drug Resistance and Future PerspectivesFuture Microbiology, 2009
- Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan SynthesisScience, 2009
- Multidrug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV communityCurrent Opinion in Infectious Diseases, 2009
- Biosynthesis of D‐arabinose in mycobacteria – a novel bacterial pathway with implications for antimycobacterial therapyThe FEBS Journal, 2008
- The biological cost of mutational antibiotic resistance: any practical conclusions?Current Opinion in Microbiology, 2006
- Genes required for mycobacterial growth defined by high density mutagenesisMolecular Microbiology, 2003